Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2923-2934

  Gore, S D ^a   Carducci, M A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Butyrate; Histone deacetylase; Phase I; Phenylbutyrate

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINO ACID; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID DERIVATIVE; CD11B ANTIGEN; DNA; DNA BASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; HEMOGLOBIN F; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H3; HISTONE H4; HYBRID PROTEIN; LYSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENYLACETIC ACID; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RETINOIC ACID; STEROID RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRIBUTYRIN; TRICHOSTATIN A; UNINDEXED DRUG;

ABDOMINAL PAIN; ACETYLATION; ALOPECIA; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG POTENCY; DRUG RESEARCH; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MYALGIA; NAUSEA; NONHUMAN; PHENOTYPE; RASH; RAT; REGULATOR GENE; SIDE EFFECT; TREATMENT INDICATION; TUMOR CELL; VOMITING;

EID: 0033672431     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2923     Document Type: Article

References (79)

1. Role of chromatin structure in the regulation of transcription by RNA polymerase II
2. Chromatin remodeling and transcriptional regulation
3. Covalent modifications of histones: Expression from chromatin templates
4. A direct link between core histone acetylation and transcriptionally active chromatin
5. Histone acetylation and transcriptional regulatory mechanisms
6. A positive role for histone acetylation in transcription factor access to nucleosomal DNA
7. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro
8. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function
9. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo
10. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AMLI-ETO leukemia cells
11. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia
12. Role of the histone deacetylase complex in acute promyelocytic leukaemia
13. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to retinoic acid in acute promyelocytic leukemia
14. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
15. Retinoblastoma protein recruits histone deacetylase to repress transcription
16. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
17. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
18. Sodium butyrate inhibits histone deacetylation in cultured cells
19. Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences
20. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate
21. Effects of sodium butyrate, a new pharmacological agent, on cells in culture
22. K562 human erythroleukemia cell variants resistant to growth inhibition by butyrate have deficient histone acetylation
23. Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs
24. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid
25. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase
26. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation
27. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
28. Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria
29. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate
30. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-Function Analysis
31. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation and apoptosis of primary neoplastic myeloid cells
32. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines
33. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
34. Activation of a peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
35. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency
36. Treatment of episodic hyperammonemia in children with inborn errors of metabolism
37. Treatment of urea cycle disorders
38. Prospective treatment of urea cycle disorders
39. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: Review of nine cases
40. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial
41. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate
42. Induction of fetal hemoglobin production in subjects with sickle cell anaemia by oral sodium phenylbutyrate
43. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion
44. Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines
45. Stopping the biologic clock for globin gene switching
46. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child
47. Clinical pharmacology of sodium butyrate in patients with acute leukemia
48. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
49. A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
50. Phase I study of phenylacetate administered twice daily to patients with cancer
51. Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report
52. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
53. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine
54. Phenylbutyrate for refractory solid tumors: A Phase I clinical and pharmacologic evaluation
55. Improved hematopoiesis in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following administration of the putative differentiating agent sodium phenylbutyrate (SPB)
56. Clinical development of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies
57. Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB)
58. Impact of prolonged administration of the putative differentiating agent sodium phenylbutyrate (PB) on hematopoeisis in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
59. Oral sodium phenylbutyrate for refractory solid tumors: Phase I and bioavailability assessment
60. Dose escalation study of oral sodium phenylbutyrate (PB) in patients with refractory high grade astrocytomas: Maximum tolerated dose, toxicity profile, pharmacology and survival
61. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60
62. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells
63. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid
64. Inhibition of tumor growth and angiogenesis by combination of phenylbutyrate and 13-cis retinoic acid in human and rodent tumours
65. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
66. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents
67. Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate
68. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin and phenylbutyrate
69. Chemodifferentiation therapy with fluorouracil and phenylbutyrate in advanced colorectal cancer: A Phase I trial
70. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
71. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells
72. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
73. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
74. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
75. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)
76. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
77. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
78. Using monoclonal antibodies in bromodeoxyuridine-DNA analysis
79. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis